• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Nuvectis Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    9/25/25 8:23:11 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVCT alert in real time by email
    false 0001875558 0001875558 2025-09-22 2025-09-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): September 22, 2025

     

    Nuvectis Pharma, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware
    (State or Other Jurisdiction
    of Incorporation)
      001-41264
    (Commission File Number)
      86-2405608
    (IRS Employer Identification No.)

     

    1 Bridge Plaza Suite 275

    Fort Lee, NJ 07024

    (Address of Principal Executive Offices)

     

    (201) 614-3150

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

     

    Title of Class Trading Symbol(s) Exchange Name
    Common Stock NVCT Nasdaq Capital Market

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act.
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On September 22, 2025, the Board of Directors (the “Board”) of Nuvectis Pharma, Inc. (the “Company”) appointed Juan Sanchez, MD, to the Board. Dr. Sanchez will serve as a director until his term expires at the 2026 annual meeting of stockholders, at which time he will stand for election by the Company’s stockholders.

     

    Dr. Sanchez has (i) no arrangements or understandings with any other person pursuant to which he was appointed to as a director, and (ii) no family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer.

     

    Dr. Sanchez has no direct or indirect material interest in any transaction or series of similar transactions contemplated by Item 404(a) of Regulation S-K.

     

    The Company announced Dr. Sanchez’s appointment via press release on September 25, 2025. A copy of the press release is being filed as Exhibit 99.1 and incorporated by reference herein.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    The following exhibit is furnished herewith:

     

    Exhibit    
    Number   Description
    99.1   Press release issued by Nuvectis Pharma, Inc., dated September 25, 2025.
    104   Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Nuvectis Pharma, Inc.
      (Registrant)
         
    Date: September 25, 2025    
         
      By: /s/ Ron Bentsur
        Ron Bentsur
        Chairman, Chief Executive Officer and President

     

     

     

    Get the next $NVCT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVCT

    DatePrice TargetRatingAnalyst
    4/2/2025$17.00Buy
    Maxim Group
    3/17/2025$19.00Buy
    Laidlaw
    7/13/2022$21.00Buy
    Ladenburg Thalmann
    3/2/2022$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NVCT
    SEC Filings

    View All

    Nuvectis Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    9/25/25 8:23:11 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Nuvectis Pharma Inc.

    10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

    8/5/25 9:30:20 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    8/5/25 8:39:15 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mosseri Marlio Charles bought $44,768 worth of shares (5,603 units at $7.99) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/24/25 5:14:35 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mosseri Marlio Charles bought $269,532 worth of shares (33,442 units at $8.06) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/20/25 9:50:29 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaplan Matthew L. was granted 30,000 shares, increasing direct ownership by 36% to 113,760 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/12/25 4:31:16 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Nuvectis Pharma with a new price target

    Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00

    4/2/25 8:05:05 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw initiated coverage on Nuvectis Pharma with a new price target

    Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00

    3/17/25 7:40:44 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

    Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

    7/13/22 8:35:52 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

    Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion. Ron Bentsur, Chairman and Chief Executive Officer of Nuvec

    9/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

    Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that senior management will participate in the upcoming H.C. Wainwright Global Investment Conference. A Nuvectis corporate presentation delivered by Ron Bentsur, Chairman and Chief Executive Officer, will be available for on-demand viewing by conference attendees starting on Friday, September 5, 2025, at 7:00 a.m. ET. The Company will also attend virtual one-on-one meetings during the

    9/4/25 7:30:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

    The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of

    8/11/25 4:30:00 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mosseri Marlio Charles bought $44,768 worth of shares (5,603 units at $7.99) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/24/25 5:14:35 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mosseri Marlio Charles bought $269,532 worth of shares (33,442 units at $8.06) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/20/25 9:50:29 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mosseri Marlio Charles bought $171,664 worth of shares (21,167 units at $8.11) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    5/13/25 6:36:36 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

    Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion. Ron Bentsur, Chairman and Chief Executive Officer of Nuvec

    9/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

    SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

    11/5/24 10:55:09 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

    SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

    2/28/24 8:37:52 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nuvectis Pharma Inc.

    SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)

    2/6/24 8:47:33 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Financials

    Live finance-specific insights

    View All

    Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

    The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of

    8/11/25 4:30:00 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care